Navneet Majhail, MD

@BldCancerDoc

Director, Blood & Marrow Transplant Program, | President, Am Soc Transplant Cell Therapy () | | Own opinion

Cleveland, OH, USA
Vrijeme pridruživanja: listopad 2014.

Tweetovi

Blokirali ste korisnika/cu @BldCancerDoc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BldCancerDoc

  1. Prikvačeni tweet
    30. tra 2019.

    Thread of my monthly blog posts as President 👇

    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet

    Mike went to the doctor for what he thought was a bad bug bite. His actual diagnosis -- leukemia.

    Poništi
  3. proslijedio/la je Tweet

    "I told the doctors, I’m not looking for easy. I’m only looking for possible.” Jud is a four-time Olympian and head track and field coach at . See how his athlete mindset helped him through treatment for a rare cancer.

    Poništi
  4. Poništi
  5. proslijedio/la je Tweet
    3. velj

    Early-bird pricing for the Fundamentals of HCT Training Course has been extended! Get ready to join colleagues in Tampa March 14-15 for two days of skills training, case-based learning & lecture, and networking. Register by this Friday to save:

    Poništi
  6. proslijedio/la je Tweet
    Poništi
  7. proslijedio/la je Tweet
    4. velj

    Importance of reducing Time to Treat for cancer patients - improving outcomes – mjesto: msk 74th street

    , , i još njih 4
    Poništi
  8. proslijedio/la je Tweet
    3. velj

    Another fun challenge: writing a column for The Hematologist. I called my first one “Momentum” and you can check it out here:

    Poništi
  9. 4. velj

    ~2 weeks to meeting - looking forward to 👍👏🏆 research + 📚📊📝 learning + 🤩😎🥳 colleagues

    Poništi
  10. 3. velj

    On 🙏🙏🙏 to our 🌟🥇🏆 colleagues for their service and leadership (); tweeps, consider getting involved with our Women and URM special interest group

    Poništi
  11. 3. velj
    Poništi
  12. 3. velj

    It’s the insulin, stupid: How drug pricing’s simplest case study became a top issue for 2020... via

    Poništi
  13. proslijedio/la je Tweet
    2. velj

    👉🏻Beware. The study was closed after 4 patients due to toxicity. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation

    Poništi
  14. proslijedio/la je Tweet

    I examined how the Top 4 Democratic candidates (current national standings) propose to reduce Prescription Drug Costs. All great ideas. In bold font are the more unique proposals they emphasize.

    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet
    2. velj

    Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation - Biology of Blood and Marrow Transplantation

    Poništi
  16. proslijedio/la je Tweet
    2. velj

    👉🏻 engraftment syndrome😕...very common in MM. We found age and Evomela use to be significant as well (ASH 2019) 😬😩⁩ ⁦⁩ ⁦

    Poništi
  17. proslijedio/la je Tweet
    1. velj

    And the next one is MM. Look at the potential number of patients in the US!!!

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    1. velj

    Critically ill pediatric allogeneic HCT patients may benefit from early and aggressive interventions aimed at reversing the progression of multiorgan dysfunction. : Results from Merging the and Virtual Pediatric Systems Registries

    Poništi
  19. proslijedio/la je Tweet
    1. velj

    👉🏻Over 8000 patients: Transplant conditioning intensity (TCI) scored 1-6, related to NRM and relapse. Great work 👍🏻🙌🏻⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦

    Poništi
  20. 31. sij

    U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment via

    Poništi
  21. proslijedio/la je Tweet
    31. sij

    Today is the last day to take advantage of early-bird pricing for the Fundamentals of HCT Training Course. The course, in Tampa March 14-15, will provide skills to manage patients undergoing HCT, with a focus on pharmacotherapeutic management.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·